Grufity logoGrufity logo

CareDx Inc Stock Research

CDNA

9.66USD-0.22(-2.23%)Market Closed

Market Summary

USD9.66-0.22
Market Closed
-2.23%

CDNA Alerts

CDNA Stock Price

CDNA RSI Chart

CDNA Valuation

Market Cap

517.1M

Price/Earnings (Trailing)

-6.75

Price/Sales (Trailing)

1.61

EV/EBITDA

-6.61

Price/Free Cashflow

-20.49

CDNA Price/Sales (Trailing)

CDNA Profitability

EBT Margin

-23.69%

Return on Equity

-17.78%

Return on Assets

-14.11%

Free Cashflow Yield

-4.88%

CDNA Fundamentals

CDNA Revenue

Revenue (TTM)

321.8M

Revenue Y/Y

3.99%

Revenue Q/Q

3.81%

CDNA Earnings

Earnings (TTM)

-76.6M

Earnings Y/Y

-13.49%

Earnings Q/Q

-8.21%

Price Action

52 Week Range

8.1041.50
(Low)(High)

Last 7 days

-7.5%

Last 30 days

-34.4%

Last 90 days

-21.3%

Trailing 12 Months

-68.3%

CDNA Financial Health

Current Ratio

5.1

CDNA Investor Care

Shares Dilution (1Y)

1.15%

Diluted EPS (TTM)

-1.44

Peers (Alternatives to CareDx)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
275.0B
58.1B
0.21% 1.63%
23.24
4.74
3.30% 2.55%
80.1B
12.2B
-0.48% 14.17%
18.47
6.58
-24.26% -46.28%
77.3B
8.9B
-1.64% 19.14%
23.26
8.65
17.91% 41.84%
16.5B
3.4B
-9.50% -1.15%
48.37
4.85
13.67% -64.09%
MID-CAP
6.5B
820.2M
33.58% 88.13%
-11.84
7.91
31.13% -16.13%
2.6B
278.3M
-26.82% -37.82%
-16.79
9.32
92.72% 15.56%
SMALL-CAP
1.7B
296.5M
-8.83% -2.63%
-45.88
5.66
35.09% 51.62%
594.5M
137.0M
-12.82% -37.88%
-8.86
4.34
45.65% -114.55%
517.1M
321.8M
-34.40% -68.30%
-6.75
1.61
8.57% -149.86%
341.3M
516.3M
-32.04% -78.85%
-0.11
0.66
12.13% -719.59%
276.2M
450.9M
-22.02% -71.01%
17.79
0.61
-3.52% -83.51%
156.8M
-
-8.44% 22.89%
-4.41
-
- -39.92%
3.3M
3.3M
9.17% 59.66%
-0.1
1.01
-21.77% 4.40%

Financials for CareDx

Income Statement (Last 12 Months)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue1.0%321,793,000318,629,000314,859,000308,413,000296,397,000
Operating Expenses1.8%399,024,000392,139,000379,757,000356,334,000326,123,000
  S&GA Expenses3.1%96,027,00093,183,00092,292,00084,941,00077,245,000
  R&D Expenses1.7%90,388,00088,864,00085,997,00082,401,00076,525,000
EBITDA-6.9%-64,631,000-60,459,000-41,331,000-23,290,000-
EBITDA Margin-4.6%-0.20-0.19-0.13-0.08-
Earnings Before Taxes-1.5%-76,234,000-75,130,000-70,517,000-50,798,000-32,088,000
EBT Margin-0.5%-0.24-0.24-0.22-0.16-
Interest Expenses700.0%8,0001,000---
Net Income-2.9%-76,613,000-74,435,000-69,393,000-49,623,000-30,662,000
Net Income Margin-1.9%-0.24-0.23-0.22-0.16-
Free Cahsflow10.7%-25,239,000-28,258,000-20,797,000-17,413,333-
Balance Sheet
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets-0.3%543545541547567
  Current Assets-0.1%388388404411433
    Cash Equivalents8.4%90.0083.00167172348
  Inventory6.3%19.0018.0019.0018.0017.00
  Goodwill0.1%38.0038.0037.0037.0037.00
Liabilities3.9%11210898.0089.00101
  Current Liabilities8.1%76.0070.0078.0067.0077.00
Shareholder's Equity-1.3%431437444458466
  Retained Earnings-4.3%-460-441-424-402-383
  Additional Paid-In Capital1.3%899887875865854
Shares Outstanding0.0%54.0054.0053.0053.0053.00
Cashflow (Last 12 Months)
(In Millions)
* denotes actual numbers (not divided by Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations10.7%-25.24-28.26-20.80-7.13-19.29
  Share Based Compensation6.0%47.0044.0043.0040.0036.00
Cashflow From Investing4.3%-228-238-142-12748.00
Cashflow From Financing-51.3%-4.53-3.00-5.10-2.72186
  Buy BacksInfinity%1.000.00---

Risks for CDNA

What is the probability of a big loss on CDNA?

100%


Probability that CareDx stock will be more than 20% underwater in next one year

84.2%


Probability that CareDx stock will be more than 30% underwater in next one year.

46.9%


Probability that CareDx stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CDNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CareDx was unfortunately bought at previous high price.

Drawdowns

Returns for CDNA

Cumulative Returns on CDNA

10.7%


7-Year Cumulative Returns

11.3%


5-Year Cumulative Returns

-20.9%


3-Year Cumulative Returns

What are the long-term rolling returns for CDNA?

FIve years rolling returns for CareDx.

Annualized Returns

Which funds bought or sold CDNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
new
-
724,022
724,022
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-2.99
-24,000
45,000
-%
2023-02-28
Voya Investment Management LLC
unchanged
-
-109,265
222,735
-%
2023-02-21
MACQUARIE GROUP LTD
reduced
-44.9
-17,202,000
10,071,000
0.01%
2023-02-17
TRUIST FINANCIAL CORP
sold off
-100
-200,000
-
-%
2023-02-15
Steward Partners Investment Advisory, LLC
unchanged
-
-3,295
5,705
-%
2023-02-15
State of Wyoming
sold off
-100
-36,000
-
-%
2023-02-15
Financial Gravity Asset Management, Inc.
new
-
19.00
19.00
-%
2023-02-15
ALLIANCEBERNSTEIN L.P.
unchanged
-
-354,029
719,971
-%
2023-02-15
LAZARD ASSET MANAGEMENT LLC
reduced
-81.24
-115,000
16,000
-%

1–10 of 46

Latest Funds Activity

Are funds buying CDNA calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own CDNA
No. of Funds

CareDx News

Best Stocks

Fred Alger Management LLC has sold shares of CareDx, Inc ....

Best Stocks,
3 days ago

Business Wire

Marketscreener.com

InvestorsObserver

Schedule 13G FIlings of CareDx

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 13, 2023
gagnon securities llc
4.7%
2,522,063
SC 13G
Feb 15, 2023
arrowmark colorado holdings llc
7.48%
4,003,218
SC 13G
Feb 14, 2023
bellevue asset management (uk) ltd.
5.9%
3,168,448
SC 13G
Feb 10, 2023
ark investment management llc
11.56%
6,188,182
SC 13G/A
Feb 09, 2023
vanguard group inc
9.84%
5,270,397
SC 13G/A
Feb 08, 2023
invesco ltd.
0.2%
88,421
SC 13G/A
Feb 03, 2023
blackrock inc.
8.2%
4,373,662
SC 13G/A
Jan 10, 2023
alger associates inc
0.9%
503,686
SC 13G/A
Jan 10, 2023
state street corp
10.74%
5,747,244
SC 13G/A
Feb 14, 2022
alger associates inc
6.2%
3,270,973
SC 13G/A

CDNA Fair Value

CareDx fair value in different scenarios

The table shows the Fair Value estimates for CareDx for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

2.90

-69.98%

3.97

-58.90%

7.16

-25.88%

13.21

36.75%

25.43

163.25%
Current Inflation

2.82

-70.81%

3.78

-60.87%

6.56

-32.09%

11.75

21.64%

22.18

129.61%
Very High Inflation

2.73

-71.74%

3.55

-63.25%

5.84

-39.54%

10.05

4.04%

18.43

90.79%

Historical CareDx Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of CareDx

View All Filings
Date Filed Form Type Document
Mar 13, 2023
8-K
Current Report
Mar 13, 2023
SC 13G
Major Ownership Report
Mar 06, 2023
4
Insider Trading
Feb 27, 2023
10-K
Annual Report
Feb 27, 2023
8-K
Current Report
Feb 27, 2023
S-8
Employee Benefits Plan
Feb 15, 2023
SC 13G
Major Ownership Report
Feb 14, 2023
SC 13G
Major Ownership Report
Feb 13, 2023
4
Insider Trading
Feb 10, 2023
SC 13G/A
Major Ownership Report

Latest Insider Trading transactions for CDNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-02
Seeto Reginald
sold
-44,757
15.8772
-2,819
see remarks
2023-02-10
Seeto Reginald
sold
-131,386
15.479
-8,488
see remarks
2023-02-09
Seeto Reginald
sold
-178,928
16.1284
-11,094
see remarks
2023-02-08
Maag Peter
sold
-51,500
15.7543
-3,269
-
2023-02-07
Seeto Reginald
sold
-50,337
16.4019
-3,069
see remarks
2023-02-03
Seeto Reginald
sold (taxes)
-40,622
16.54
-2,456
see remarks
2023-02-03
Johnson Alexander L
sold (taxes)
-13,794
16.54
-834
chief business officer
2023-02-02
Johnson Alexander L
sold (taxes)
-35,730
17.61
-2,029
chief business officer
2023-02-02
Seeto Reginald
sold
-48,346
17.1503
-2,819
see remarks
2023-02-02
Maag Peter
sold
-85,829
17.1659
-5,000
-

1–10 of 50

Reginald Seeto
640
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Income Statement

2022-12-31
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Revenues [Abstract]   
Revenue$ 321,793$ 296,397$ 192,194
Operating expenses:   
Research and development90,38876,52548,941
Sales and marketing96,02777,24553,858
General and administrative100,39774,96448,806
Total operating expenses399,024326,123214,722
Loss from operations(77,231)(29,726)(22,528)
Other income (expense):   
Interest income, net3,762160271
Change in estimated fair value of common stock warrant liability107106(1,495)
CARES Act Provider Relief Fund004,813
Other expense, net(2,872)(2,628)(811)
Total other income (expense)997(2,362)2,778
Loss before income taxes(76,234)(32,088)(19,750)
Income tax (expense) benefit(379)1,4261,036
Net loss$ (76,613)$ (30,662)$ (18,714)
Net loss per share (Note 3):   
Basic (in dollars per share)$ (1.44)$ (0.59)$ (0.40)
Diluted (in dollars per share)$ (1.44)$ (0.59)$ (0.40)
Weighted-average shares used to compute net loss per share:   
Basic (in shares)53,321,62552,241,07646,481,772
Diluted (in shares)53,321,62552,241,07646,481,772
Testing services revenue   
Revenues [Abstract]   
Revenue$ 263,748$ 259,285$ 163,610
Operating expenses:   
Cost of testing services, product, patient and digital solutions72,28671,25143,932
Product revenue   
Revenues [Abstract]   
Revenue29,25126,83219,302
Operating expenses:   
Cost of testing services, product, patient and digital solutions17,63918,93013,847
Patient and digital solutions   
Revenues [Abstract]   
Revenue28,79410,2809,282
Operating expenses:   
Cost of testing services, product, patient and digital solutions$ 22,287$ 7,208$ 5,338

CDNA Balance Sheet

2022-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 89,921$ 348,485
Marketable securities203,1680
Accounts receivable66,31259,761
Inventory19,23217,186
Prepaid and other current assets9,2167,928
Total current assets387,849433,360
Property and equipment, net35,52922,044
Operating leases right-of-use assets34,68917,993
Intangible assets, net43,05150,195
Goodwill37,52336,983
Restricted cash522211
Other assets3,8285,835
Total assets542,991566,621
Current liabilities:  
Accounts payable9,94213,337
Accrued compensation16,90226,042
Accrued and other liabilities49,13137,922
Total current liabilities75,97577,301
Deferred tax liability0415
Common stock warrant liability32139
Deferred payments for intangible assets2,4185,041
Operating lease liability, less current portion33,40617,394
Other liabilities249455
Total liabilities112,080100,745
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock: $0.001 par value; 10,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 202100
Common stock: $0.001 par value; 100,000,000 shares authorized at December 31, 2022 and 2021; 53,583,301 and 52,923,360 shares issued at December 31, 2022 and 2021, respectively; 53,533,250 and 52,923,360 shares outstanding at December 31, 2022 and 2021, respectively5252
Additional paid-in capital898,806853,683
Accumulated other comprehensive loss(7,503)(4,670)
Accumulated deficit(460,444)(383,189)
Total stockholders’ equity430,911465,876
Total liabilities and stockholders’ equity$ 542,991$ 566,621